Serum levels one month after the vaccine's third dose neutralized omicron to levels comparable with those observed for the wild-type SARS-CoV-2 spike protein after two doses, the companies said.
Pfizer and BioNTech said two shots of the vaccine may not be sufficient to protect against the variant, although they may still protect against severe forms of the disease.
The companies said they have "high confidence" that they can deliver an omicron-based vaccine in March 2022, if needed.
Price: 52.69, Change: +0.97, Percent Change: +1.88
|CME Group SOFR Futures Hit New Single-Day Trading Vo...|
|Fox Corp Unit Fox News Media's International Streami...|
|Research Alert: CFRA Maintains Hold Opinion On Share...|
|Market Chatter: National Labor Relations Board Repor...|
|Top Cryptocurrencies Retreat Alongside US Stocks; Bi...|